We are currently working on this topic, answering the following questions:
What is the scientific basis for extending such screening programmes to other cancers e.g. lung, prostate and gastric cancers, and ensuring their feasibility throughout the EU?
Which are the main scientific elements to consider, and best practices to promote, for optimising risk-based cancer screening and early diagnosis throughout the EU?
The European Commission will make a proposal by 2022 to update the Council Recommendation on cancer screening to ensure it reflects the latest available scientific evidence. One of the objectives will be to consider the extension of cancer screening beyond breast, colorectal and cervical cancer to include prostate, lung and gastric cancer, and other cancers if supported by scientific evidence.
In advance of this proposal, the European Commission's Group of Chief Scientific Advisors will develop a Scientific Opinion on this topic. To inform this Opinion, SAPEA has been asked to review the evidence on the topic.
To ensure we deliver evidence of the highest standard in a transparent way, our work is guided by a set of principles and procedures which can be found in our Quality Assurance Guidelines.
Initial scoping and exploratory work for this topic was conducted by FEAM on behalf of SAPEA in 2020 and 2021. The final scoping paper from the European Commission was informed by this work and was published on 4 May 2021.
Starting with the publication of this scoping paper, we will follow the steps below:
For more information about SAPEA's work on this topic, please contact FEAM.